3,984 Shares in Natera, Inc. (NASDAQ:NTRA) Purchased by Silverleafe Capital Partners LLC

Silverleafe Capital Partners LLC acquired a new position in Natera, Inc. (NASDAQ:NTRA - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 3,984 shares of the medical research company's stock, valued at approximately $631,000.

Other hedge funds have also recently made changes to their positions in the company. Natixis Advisors LLC grew its position in Natera by 6.4% in the 2nd quarter. Natixis Advisors LLC now owns 24,584 shares of the medical research company's stock valued at $2,662,000 after acquiring an additional 1,486 shares in the last quarter. CIBC Asset Management Inc increased its stake in Natera by 20.8% during the 2nd quarter. CIBC Asset Management Inc now owns 3,366 shares of the medical research company's stock worth $365,000 after buying an additional 580 shares during the period. Rhumbline Advisers lifted its holdings in Natera by 4.1% during the 2nd quarter. Rhumbline Advisers now owns 139,030 shares of the medical research company's stock worth $15,056,000 after buying an additional 5,490 shares in the last quarter. TD Asset Management Inc purchased a new position in Natera in the 2nd quarter valued at approximately $1,235,000. Finally, Victory Capital Management Inc. grew its stake in shares of Natera by 234.9% in the second quarter. Victory Capital Management Inc. now owns 302,728 shares of the medical research company's stock worth $32,782,000 after acquiring an additional 212,322 shares in the last quarter. Hedge funds and other institutional investors own 99.90% of the company's stock.

Insider Activity at Natera

In related news, insider Solomon Moshkevich sold 256 shares of the firm's stock in a transaction dated Tuesday, October 22nd. The shares were sold at an average price of $120.07, for a total value of $30,737.92. Following the completion of the sale, the insider now owns 111,891 shares in the company, valued at $13,434,752.37. This trade represents a 0.23 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider John Fesko sold 669 shares of Natera stock in a transaction that occurred on Monday, December 23rd. The shares were sold at an average price of $159.60, for a total value of $106,772.40. Following the completion of the sale, the insider now directly owns 114,142 shares in the company, valued at $18,217,063.20. This represents a 0.58 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 127,932 shares of company stock worth $20,635,430 in the last three months. Insiders own 7.60% of the company's stock.

Natera Stock Performance

NTRA stock traded up $4.66 on Monday, hitting $172.26. The company's stock had a trading volume of 1,345,841 shares, compared to its average volume of 1,092,605. Natera, Inc. has a 1 year low of $59.80 and a 1 year high of $175.63. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. The stock has a market cap of $22.74 billion, a price-to-earnings ratio of -97.88 and a beta of 1.65. The firm has a 50 day moving average of $156.10 and a two-hundred day moving average of $130.60.

Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.57) by $0.31. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The firm had revenue of $439.80 million for the quarter, compared to analyst estimates of $361.43 million. During the same quarter last year, the company posted ($0.95) earnings per share. The business's revenue was up 63.9% on a year-over-year basis. Equities analysts predict that Natera, Inc. will post -1.61 EPS for the current fiscal year.

Analyst Ratings Changes

NTRA has been the topic of several analyst reports. Leerink Partners increased their price objective on Natera from $140.00 to $150.00 and gave the company an "outperform" rating in a research note on Thursday, October 17th. Robert W. Baird increased their price target on Natera from $120.00 to $160.00 and gave the company an "outperform" rating in a research report on Wednesday, November 13th. Craig Hallum boosted their price objective on Natera from $121.00 to $157.00 and gave the stock a "buy" rating in a research report on Wednesday, November 13th. The Goldman Sachs Group upped their target price on shares of Natera from $125.00 to $140.00 and gave the stock a "buy" rating in a research note on Wednesday, October 16th. Finally, TD Cowen lifted their price target on shares of Natera from $155.00 to $175.00 and gave the stock a "buy" rating in a research note on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $153.67.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.